Financial Performance - For the year ending December 31, 2025, GHW International reported revenue of approximately RMB 4,113.2 million, an increase of about RMB 251.2 million or 6.5% compared to the same period in 2024[5] - The gross profit for the same period was approximately RMB 360.9 million, a decrease of about RMB 30.2 million or 7.7% compared to 2024[5] - The net profit for the year was approximately RMB 13.4 million, an increase of about RMB 0.5 million or 3.9% compared to 2024[5] - Basic earnings per share for the year were approximately RMB 0.013, a decrease of about RMB 0.001 or 7.1% compared to 2024[5] - The company recorded revenue of approximately RMB 4,113.2 million for the year ended December 31, 2025, representing a 6.5% increase from RMB 3,862.0 million in 2024[53] - Net profit increased from approximately RMB 12.9 million in 2024 to approximately RMB 13.4 million in 2025[53] - Total revenue for the year ending December 31, 2025, reached RMB 4,113.2 million, up from RMB 3,861.9 million in 2024, representing a growth of approximately 6.5%[56] Revenue Breakdown - Revenue from the methylamine product series was RMB 1,306,777,000 in 2025, a decrease of 3.8% from RMB 1,359,067,000 in 2024[19] - Revenue from iodine derivatives and related products increased significantly to RMB 1,262,877,000 in 2025, up 27.3% from RMB 991,926,000 in 2024[19] - Revenue from the Jin Hai Wei New Materials segment grew by 3.4% to RMB 922.6 million, driven by the sales of ethylene oxide and monomer polyether starting in 2025[53] - The Green Products segment saw revenue increase by 40.5% to RMB 281.5 million, primarily due to increased sales of cashew phenol and rising raw material costs[53] - Revenue from the iodine derivatives segment increased by 27.3% from RMB 991.9 million to RMB 1,262.9 million, driven by increased market share and penetration[61] - Revenue from green products, particularly cashew phenol, grew by 40.5% due to recovery in the European market and increased export demand[65] Expenses and Costs - Sales costs rose from approximately RMB 3,470.9 million in 2024 to RMB 3,752.3 million in 2025, primarily due to increased production costs of iodine and related products[72] - Gross profit decreased from approximately RMB 391.0 million in 2024 to RMB 360.9 million in 2025, with the overall gross margin declining from 10.1% to 8.8%[73] - Research and development expenses for the year were RMB 57.1 million, an increase from RMB 48.9 million in 2024[6] - Research and development expenses increased from approximately RMB 48.9 million in 2024 to RMB 57.1 million in 2025, driven by R&D activities for new products[81] - Sales and distribution expenses decreased from approximately RMB 172.6 million in 2024 to RMB 147.3 million in 2025, attributed to lower logistics costs[78] - Administrative expenses slightly decreased from approximately RMB 137.8 million in 2024 to RMB 136.5 million in 2025, due to reduced consulting fees[80] Assets and Liabilities - Total assets less current liabilities amounted to RMB 864.7 million, an increase from RMB 797.4 million in 2024[11] - Non-current assets increased to RMB 947.5 million from RMB 925.2 million in 2024[8] - Current liabilities decreased to RMB 1,203.5 million from RMB 1,249.1 million in 2024[11] - The company’s total equity increased to RMB 635.7 million from RMB 621.6 million in 2024[11] - Borrowings, including loans from related parties, were approximately RMB 810.4 million as of December 31, 2025, down from RMB 852.2 million in 2024, with a debt-to-equity ratio of 127.5%[90] Taxation - The company's income tax provision for the Cayman Islands is exempt, with no tax provisions made for subsidiaries in the US, Seychelles, Russia, Hong Kong, and Canada due to no estimated taxable profits in the two years[30] - The effective tax rate for the Ukrainian subsidiary is 18% for the year, while the applicable tax rate for mainland China subsidiaries is 25%, with a reduced rate of 15% for high-tech enterprises[31] - The current tax expense for 2025 is RMB 7,637,000, an increase from RMB 3,578,000 in 2024, while the total tax expense for 2025 is RMB 4,361,000 compared to a negative RMB 339,000 in 2024[33] - Income tax expenses increased from a tax credit of approximately RMB 3 million for the year ending December 31, 2024, to a tax expense of about RMB 44 million for the year ending December 31, 2025, primarily due to increased profits from subsidiaries in Vietnam[84] Shareholder Information - The board of directors has resolved not to recommend the payment of any final dividend for the year ending December 31, 2025[5] - The company has not declared or paid any dividends during the two years and has no plans to do so since the reporting period[34] - The group did not recommend any final dividend for the year ending December 31, 2025, consistent with 2024[106] - The annual general meeting is scheduled for May 12, 2026, with a notice to be sent to shareholders according to the company's articles of association and applicable laws[121] - Shareholder registration will be suspended from May 7 to May 12, 2026, to determine eligibility for attending and voting at the annual general meeting[122] Strategic Initiatives - The company is pursuing global expansion through strategic investments and partnerships, optimizing its supply chain to improve operational efficiency[52] - The company plans to enhance supply chain resilience and expand into diverse regional markets through smart manufacturing facilities and customized products, despite market uncertainties[87] - The group plans to enhance brand influence and develop self-owned brand products through collaborations with third-party clients and KOLs for live-streaming sales[68] Market Conditions - The chemical industry in China faces challenges such as weak demand and supply-demand imbalances, impacting profitability across the sector[51] - The company faces significant market volatility in 2026 due to escalating upstream energy-related costs and cautious downstream demand, impacting the chemical market[86] Risk Management - The company’s credit risk is primarily associated with trade receivables, with management implementing measures to minimize this risk through credit limits and monitoring[96] - The group maintained a prudent treasury policy, ensuring good liquidity throughout the year[100] - The group faced foreign exchange risks due to transactions primarily denominated in RMB and USD, with no financial instruments used to hedge these risks[101] - The audit committee has reviewed the financial reporting procedures and risk management systems, ensuring compliance with relevant regulations[113]
GHW INTL(09933) - 2025 - 年度业绩